Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 94Neoplasm Metastasis 9Prostatic Neoplasms, Castration-Resistant 5Breast Neoplasms 3Neoplasms 2Metastatic Castration Resistant Prostate Cancer 2Castration-resistant Prostate Cancer 2Urinary Bladder Neoplasms 1Stage II Prostate Adenocarcinoma 1Salivary Glands Tumors 1Rate of PSA Response in Oligometastatic,CRPC Undergoing SBRT in Combination With Abiraterone Acetate (AA), Compared to Patients Treated With AA Alone 1Prostate Cancer Metastatic 1Prostate Adenocarcinoma 1Pharmacogenetic Study 1Oligometastatic Prostate Carcinoma 1Neoadjuvant Therapy 1Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 1Metastatic Hormone Refractory Prostate Cancer 1Metastatic Castration-resistent Prostate Cancer 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Metastatic Castration-resistant Prostate Cancer 1Metastatic Castration-Resistant Prostate Cancer 1Dementia 1Cushing Syndrome 1Cognitive Dysfunction 1Castrate-resistant Prostate Cancer 1Carcinoma, Transitional Cell 1Cancer Pain 1Adrenocortical Carcinoma 1Adenocarcinoma 1

Interventions

cabozantinib 1Prednisone 1Nivolumab 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Metastatic Hormone Refractory Prostate Cancer × Abiraterone Acetate × Clear all
NCT04477512 2025-11-12

Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)

Washington University School of Medicine

Phase 1 Completed
18 enrolled
Genitourinary

Metastatic Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡